In vitro activity of therapeutic antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5

被引：39

作者：

Touret, Franck ^{[1
]}

Baronti, Cecile ^{[1
]}

Pastorino, Boris ^{[1
]}

Villarroel, Paola Mariela Saba ^{[1
]}

Ninove, Laetitia ^{[1
]}

Nougairede, Antoine ^{[1
]}

de Lamballerie, Xavier ^{[1
]}

机构：

[1] UVE Aix Marseille Univ, Unite Virus Emergents, IRD 190, Inserm 1207, Marseille, France

来源：

SCIENTIFIC REPORTS | 2022年 / 12卷 / 01期

关键词：

D O I：

10.1038/s41598-022-16964-z

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

The replacement of the Omicron BA.1 variant of SARS-CoV-2 by the BA.2 and the rapid growth of the BA.5 sub lineage, which have both different sets of mutations in the spike glycoprotein, alters the spectrum of activity of therapeutic antibodies currently licensed in the European Union. Using clinical strains of the Omicron BA.2 and BA.5 variants, we compared the neutralising power of monoclonal antibodies against the Omicron BA.1, BA.2 and BA.5 variants, using an ancestral strain (lineage B.1, D614G) and a Delta variant strain as reference. Sotrovimab/Vir-7831 is less active against BA.2 than against BA.1 (fold change reduction similar to 1,4) and even less active against BA.5 (fold change reduction similar to 2.7). Within the Evusheld /AZD7442 cocktail, Cilgavimab/AZD1061 is more active against BA.2 and BA.5 than against BA.1 (fold change increase similar to 32), whilst the very low activity of Tixagevimab/AZD8895 against BA.1 is not enhanced against BA.2 nor BA.5. In total, compared to BA.1, the activity of the Evusheld/AZD7442 is significantly improved against BA.2 while BA.5 is intermediate but closer to BA.2.

引用

页数：6

共 24 条

[1] Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies [J].

Bruel, Timothee ;

Hadjadj, Jerome ;

Maes, Piet ;

Planas, Delphine ;

Seve, Aymeric ;

Staropoli, Isabelle ;

Guivel-Benhassine, Florence ;

Porrot, Francoise ;

Bolland, William-Henry ;

Nguyen, Yann ;

Casadevall, Marion ;

Charre, Caroline ;

Pere, Helene ;

Veyer, David ;

Prot, Matthieu ;

Baidaliuk, Artem ;

Cuypers, Lize ;

Planchais, Cyril ;

Mouquet, Hugo ;

Baele, Guy ;

Mouthon, Luc ;

Hocqueloux, Laurent ;

Simon-Loriere, Etienne ;

Andre, Emmanuel ;

Terrier, Benjamin ;

Prazuck, Thierry ;

Schwartz, Olivier .

NATURE MEDICINE, 2022, 28 (06) :1297-+

[2]

Cameroni E, 2022, NATURE, V602, P664, DOI [10.1038/s41586-021-04386-2, 10.1101/2021.12.12.472269]

[3] Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021 [J].

Campbell, Finlay ;

Archer, Brett ;

Laurenson-Schafer, Henry ;

Jinnai, Yuka ;

Konings, Franck ;

Batra, Neale ;

Pavlin, Boris ;

Vandemaele, Katelijn ;

Van Kerkhove, Maria D. ;

Jombart, Thibaut ;

Morgan, Oliver ;

de Waroux, Olivier le Polain .

EUROSURVEILLANCE, 2021, 26 (24) :1-6

[4]

Cathcart AL., 2021, bioRxiv, DOI DOI 10.1101/2021.03.09.434607

[5] The viral capping enzyme nsP1: a novel target for the inhibition of chikungunya virus infection [J].

Delang, L. ;

Li, C. ;

Tas, A. ;

Querat, G. ;

Albulescu, I. C. ;

De Burghgraeve, T. ;

Guerrero, N. A. Segura ;

Gigante, A. ;

Piorkowski, G. ;

Decroly, E. ;

Jochmans, D. ;

Canard, B. ;

Snijder, E. J. ;

Perez-Perez, M. J. ;

van Hemert, M. J. ;

Coutard, B. ;

Leyssen, P. ;

Neyts, J. .

SCIENTIFIC REPORTS, 2016, 6

[6] Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail [J].

Dong, Jinhui ;

Zost, Seth J. ;

Greaney, Allison J. ;

Starr, Tyler N. ;

Dingens, Adam S. ;

Chen, Elaine C. ;

Chen, Rita E. ;

Case, James Brett ;

Sutton, Rachel E. ;

Gilchuk, Pavlo ;

Rodriguez, Jessica ;

Armstrong, Erica ;

Gainza, Christopher ;

Nargi, Rachel S. ;

Binshtein, Elad ;

Xie, Xuping ;

Zhang, Xianwen ;

Shi, Pei-Yong ;

Logue, James ;

Weston, Stuart ;

McGrath, Marisa E. ;

Frieman, Matthew B. ;

Brady, Tyler ;

Tuffy, Kevin M. ;

Bright, Helen ;

Loo, Yueh-Ming ;

McTamney, Patrick M. ;

Esser, Mark T. ;

Carnahan, Robert H. ;

Diamond, Michael S. ;

Bloom, Jesse D. ;

Crowe, James E., Jr. .

NATURE MICROBIOLOGY, 2021, 6 (10) :1233-+

[7]

DRIOUICH J.-S., 2022, RES SQ, DOI [10.21203/rs.3.rs-1399448/v1, DOI 10.21203/RS.3.RS-1445747/V1]

[8] Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab [J].

Gupta, Anil ;

Gonzalez-Rojas, Yaneicy ;

Juarez, Erick ;

Casal, Manuel Crespo ;

Moya, Jaynier ;

Falci, Diego R. ;

Sarkis, Elias ;

Solis, Joel ;

Zheng, Hanzhe ;

Scott, Nicola ;

Cathcart, Andrea L. ;

Hebner, Christy M. ;

Sager, Jennifer ;

Mogalian, Erik ;

Tipple, Craig ;

Peppercorn, Amanda ;

Alexander, Elizabeth ;

Pang, Phillip S. ;

Free, Almena ;

Brinson, Cynthia ;

Aldinger, Melissa ;

Shapiro, Adrienne E. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (21) :1941-1950

[9] A pan-serotype dengue virus inhibitor targeting the NS3-NS4B interaction [J].

Kaptein, Suzanne J. F. ;

Goethals, Olivia ;

Kiemel, Dominik ;

Marchand, Arnaud ;

Kesteleyn, Bart ;

Bonfanti, Jean-Francois ;

Bardiot, Dorothee ;

Stoops, Bart ;

Jonckers, Tim H. M. ;

Dallmeier, Kai ;

Geluykens, Peggy ;

Thys, Kim ;

Crabbe, Marjolein ;

Chatel-Chaix, Laurent ;

Muenster, Max ;

Querat, Gilles ;

Touret, Franck ;

de Lamballerie, Xavier ;

Raboisson, Pierre ;

Simmen, Kenny ;

Chaltin, Patrick ;

Bartenschlager, Ralf ;

Van Loock, Marnix ;

Neyts, Johan .

NATURE, 2021, 598 (7881) :504-+

[10] Covid-19: AstraZeneca says its antibody drug AZD7442 is effective for preventing and reducing severe illness [J].

Mahase, Elisabeth .

BMJ-BRITISH MEDICAL JOURNAL, 2021, 375 :n2860

← 1 2 3 →